ID (ISN) del documento | 52020 |
Número CIS |
89-1258 |
ISSN - Título de la serie |
0002-8894 - American Industrial Hygiene Association Journal |
Año |
1988 |
Número de serie |
|
Autor(es) |
Pyy L., Sorsa M., Hakala E. |
Título |
Ambient monitoring of cyclophosphamide in manufacture and hospitals |
Información bibliográfica |
June 1988, Vol.49, No.6, p.314-317. Illus. 6 ref. |
Resumen |
Cyclophosphamide (CP), one of the most commonly used cytostatic drugs, is a human carcinogen. In this study, CP was a model compound for the identification of potential exposure situations in the various phases of its manufacture and hospital use. Ambient air samples were taken in the various phases and analysed for CP. A low detection limit (0.05µg/m3 for a 1m3 sample volume) was obtained for CP by the mass spectrometric method developed for this study. The detection limit was 1µg/m3 with high performance liquid chromatography. The correlation between the 2 methods was good. The highest potential exposure situations were found during specific operations at the end of the manufacturing process. During these operations the airborne CP concentrations may rise as high as several hundred µg/m3, and the workers must use supplied air respirators, gloves and protective clothing. For the measurements in hospital use, air samples were taken from flow hoods. During normal working practices, no measurable amounts of CP could be observed. A filter from a flow hood, however, contained CP in measurable quantities, showing that occasional spilling may occur. |
Descriptores (primarios) |
ciclofosfamida; valoración de la exposición; industria farmacéutica; toma de muestras y análisis; hospitales |
Descriptores (secundarios) |
substancias cancerígenas; descripción del procedimiento; toma de muestras del aire; citostáticos |
Tipo de documento |
D - Artículos periódicos |
Tema(s) |
Sustancias tóxicas y peligrosas
|
Broad subject area(s) |
Riesgos químicos
|
Navegación por categoria(s) |
Exposure evaluation Heterocyclic compounds Health care services Pharmaceutical industry
|